Pain Therapeutics, Inc.  

(Public, NASDAQ:PTIE)   Watch this stock  
Find more results for pain
4.00
-0.24 (-5.66%)
Jun 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.92 - 4.28
52 week 3.39 - 21.00
Open 4.25
Vol / Avg. 56,738.00/64,235.00
Mkt cap 26.75M
P/E     -
Div/yield     -
EPS -1.81
Shares 6.59M
Beta 2.36
Inst. own 37%
Jul 17, 2017
Q2 2017 Pain Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Apr 25, 2017
Q1 2017 Pain Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -59.62% -57.99%
Return on average equity -62.23% -61.87%
Employees 9 -
CDP Score - -

Address

7801 N Capital of Texas Hwy Ste 260
AUSTIN, TX 78731-1192
United States - Map
+1-512-5012444 (Phone)
+1-512-6140414 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company's lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company's other products is FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use. The Company has developed REMOXY to make oxycodone difficult to abuse yet provide approximately 12 hours of steady pain relief when used by patients. REMOXY is intended to meet the needs of healthcare prescribing opioid drugs and seeking to minimize the risks of drug diversion, abuse or accidental patient misuse. The Company's drug candidate FENROCK is an abuse-deterrent transdermal pain patch in the pre-Investigational new drug-stage of development. FENROCK is designed to provide pain relief over 72 hours.

Officers and directors

Remi Barbier Chairman of the Board, President, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Nadav Friedmann Chief Medical and Operating Officer, Director
Age: 72
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Michael Marsman Pharm.D. Senior Vice President - Regulatory Affairs
Bio & Compensation  - Reuters
Robert Z. Gussin Ph.D. Independent Director
Age: 77
Bio & Compensation  - Reuters
Michael J. O' Donnell Esq. Independent Director
Age: 56
Bio & Compensation  - Reuters
Saira Ramasastry Independent Director
Age: 39
Bio & Compensation  - Reuters
Sanford R. Robertson Independent Director
Age: 85
Bio & Compensation  - Reuters
Patrick J. Scannon M.D., Ph.D. Independent Director
Age: 67
Bio & Compensation  - Reuters